NeuroPace (NASDAQ: NPCE - Get Free Report) and CapsoVision (NASDAQ: CV - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings. Insider and Institutional Ownership 78.8% of NeuroPace shares are

Bank of America Corp DE reduced its stake in shares of NeuroPace, Inc. (NASDAQ: NPCE) by 85.5% during the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 24,698 shares of the company's stock after selling 145,741 shares during the period. Bank of America Corp DE owned

NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?

NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.

BlackRock Inc. bought a new stake in NeuroPace, Inc. (NASDAQ: NPCE) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,477,603 shares of the company's stock, valued at approximately $39,369,000. BlackRock Inc. owned about 7.27% of NeuroPace as of

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming 2026 Cantor Global Healthcare Conference. NeuroPace management will participate in a fireside chat discussion on Wednesday, September 9 at 10:55am EDT, and host one-on-one meetings with investors during the conference. The fireside chat will be accessible via a.

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference. NeuroPace management will participate in a fireside chat discussion on Tuesday, September 8 at 8:00am EDT, and host one-on-one meetings with investors during the conference. The fireside chat will be accessible via.

NPCE's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company works through the FDA review process.

NPCE's stronger RNS adoption, narrowing losses and AI expansion support growth, but premium valuation, liquidity and regulatory risks warrant patience.

NeuroPace's stronger RNS growth, raised 2026 guidance and AI expansion face a less certain IGE regulatory path after the FDA setback.